Tag Archives: secondary patients

FOURIER: eficacia del evolocumab para alcanzar niveles ultra bajos de LDL

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

FOURIER: Efficacy of Evolocumab for Ultra-Low LDL Levels

It seems that a LDL level of 70 mg/dL is no longer low enough for high-risk secondary patients; in consequence, this study attempted to set a new target, one that appears almost impossible to reach: 40 mg/dL or lower. This study, simultaneously presented at the European Society of Cardiology Congress 2017 and published in The Lancet, showed

Top